Fairscale Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fairscale Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.31K	Buy	+14	New	+$3.56K	﹤0.01%	408

Other funds holding ALNY

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Fairscale Capital's ALNY Position: Q3 2026 in Review

Fairscale Capital opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 14 shares worth $2.31K. The stake represents ﹤0.01% of the portfolio and ranks #408 among its holdings.

353 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Fairscale Capital held 14 shares of Alnylam Pharmaceuticals worth $2.31K as of Q3 2026.
Alnylam Pharmaceuticals was a new Fairscale Capital position in Q3 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Fairscale Capital's portfolio in Q3 2026, its #408 holding.
353 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Fairscale Capital's 13F filing for Q3 2026, filed 4 Nov 2026.